Overview

Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.
Phase:
Phase 3
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Metformin
Rosiglitazone
Sitagliptin Phosphate
Criteria
Inclusion Criteria:

- Patient has Type 2 diabetes

- Currently taking metformin >1500 mg/day for at least 10 weeks

- Male or female

Exclusion Criteria:

- Patient has peripheral edema

- History of type 1 diabetes

- Patient required insulin within prior 8 weeks

- Have participated or are currently participating in another study with an
investigational compound or device within 12 weeks of starting this study

- Participating in a weight loss program